Menu
← Oncology Approval Tracker
FDA DECISION ·
Imfinzi + BCG
durvalumab with Bacillus Calmette–Guérin · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
LAMPGEN ANALYSIS
Why it matters
This combines systemic checkpoint therapy with intravesical BCG in a BCG-naïve high-risk population. It differs clinically from treatments used after BCG failure.
What research teams should watch
Track prior BCG exposure, risk-defining pathology and instillation completion. Coordinate urology surveillance with systemic immune-toxicity reporting.
PRIMARY RECORDS